On this page

Sterile Water

Water · Injection

Prescription NDA TE AP RLD Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Sterile Water
Generic name
Water
Dosage form
Injection
Route
Intramuscular
Marketing category
NDA · NDA
Labeler
Fresenius Kabi USA, LLC
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
1
NDC product codes
26
Packages
40
Data completeness
84% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Water 1 mL/mL 1053154 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Injection
Route of administration
Intramuscular
Presentations
66

Regulatory status

Source: Drugs@FDANDC Directory
Application number
018801
Application type
NDA · New Drug Application
Approval date
October 27, 1982
Sponsor
HOSPIRA
Products on application
6
Submissions recorded
26
Products approved under application 018801.
Product Trade name Form Strength Ingredient Status TE Flags
018801-001 STERILE WATER FOR INJECTION LIQUID STERILE WATER FOR INJECTION Discontinued — RLD
018801-002 STERILE WATER FOR INJECTION LIQUID STERILE WATER FOR INJECTION Prescription AP RLD RS
018801-003 STERILE WATER FOR INJECTION LIQUID STERILE WATER FOR INJECTION Prescription AP RLD RS
018801-004 STERILE WATER FOR INJECTION LIQUID STERILE WATER FOR INJECTION Prescription — RLD RS
018801-005 STERILE WATER FOR INJECTION LIQUID STERILE WATER FOR INJECTION Prescription — RLD RS
018801-006 STERILE WATER FOR INJECTION LIQUID STERILE WATER FOR INJECTION Prescription — RLD RS

Therapeutic equivalence

Source: Orange Book
TE code
AP
Reference Listed Drug
Yes
Reference Standard
Yes

What this rating means: Therapeutically equivalent — bioequivalence demonstrated (parenteral aqueous solutions)

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 018801.
Type No. Action Status Date Review
Supplement 40 Manufacturing (CMC) Approved December 21, 2016 Standard
Supplement 39 Manufacturing (CMC) Approved March 29, 2016 Standard
Supplement 36 Manufacturing (CMC) Approved August 1, 2014 Standard
Supplement 38 Manufacturing (CMC) Approved June 12, 2014 Standard
Supplement 34 Manufacturing (CMC) Approved July 2, 2009 Standard
Supplement 23 Manufacturing (CMC) Approved April 7, 2004 Standard
Supplement 20 Manufacturing (CMC) Approved February 16, 2001 Standard
Supplement 18 Manufacturing (CMC) Approved June 16, 2000 Standard
Supplement 19 Manufacturing (CMC) Approved May 4, 2000 Standard
Supplement 15 Manufacturing (CMC) Approved August 31, 1999 Standard
Supplement 17 Manufacturing (CMC) Approved May 28, 1999 Standard
Supplement 16 Manufacturing (CMC) Approved May 27, 1999 Standard
Supplement 14 Manufacturing (CMC) Approved August 14, 1998 Standard
Supplement 13 Labeling Approved May 13, 1998 Standard
Supplement 11 Manufacturing (CMC) Approved January 17, 1997 Standard
Supplement 12 Manufacturing (CMC) Approved August 29, 1996 Standard
Supplement 10 Manufacturing (CMC) Approved April 17, 1996 Standard
Supplement 8 Manufacturing (CMC) Approved June 14, 1989 Standard
Supplement 7 Manufacturing (CMC) Approved October 21, 1988 Standard
Supplement 6 Manufacturing (CMC) Approved August 7, 1985 Standard
Supplement 4 Manufacturing (CMC) Approved March 15, 1985 Standard
Supplement 5 Manufacturing (CMC) Approved October 22, 1984 Standard
Supplement 2 Manufacturing (CMC) Approved June 14, 1984 Standard
Supplement 1 Manufacturing (CMC) Approved January 25, 1984 Standard
Supplement 3 Manufacturing (CMC) Approved January 17, 1984 Standard
Original application 1 Type 5 - New Formulation or New Manufacturer Approved October 27, 1982 Standard

Review documents

  • 0 · Supplement · July 8, 2009
  • 0 · Supplement · April 20, 2004

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20251022). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20251022 HUMAN PRESCRIPTION DRUG · 20250529 HUMAN PRESCRIPTION DRUG · 20250108 HUMAN PRESCRIPTION DRUG · 20240410

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE Sterile Water for Irrigation is indicated for use as an irrigating fluid or pharmaceutic aid. Sterile Water may also be used as an adjunct in the preparation of non-intravenously administered nutrient mixtures (see DOSAGE AND ADMINISTRATION ).

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION This solution is for intravenous use only after admixture or dilution. Do not inject until made approximately isotonic by addition of appropriate solute. Following suitable admixture of prescribed drugs, the dosage is usually dependent upon the age, weight and clinical condition of the patient as well as laboratory determinations. See directions accompanying drugs. The dosage and administration of Sterile Water for Injection USP is dependent upon the recommended dosage and administration of the solute used. Fluid administration should be based on calculated maintenance or replacement fluid requirements for each patient. Some additives may be incompatible. Consult with pharmacist. When performing admixture or dilution, use aseptic techniques. Mix thoroughly. Do not store. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS Sterile Water for Injection, USP must be made approximately isotonic prior to use.

WARNINGS This solution is for compounding only, not for direct infusion. Hypotonic and hemolytic. Do not inject until made approximately isotonic by addition of an appropriate solute, due to the possibility of hemolysis. The administration of intravenous solutions can cause fluid and/or solute overload resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema. The risk of dilutional states is inversely proportional to the electrolyte concentration. WARNING: This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum. Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS Refer to the package insert of the solute used. Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia. The physician should also be alert to the possibility of adverse reactions to drug additives. Prescribing information for drug additives to be administered in this manner should be consulted. If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.

Drug Interactions

openFDA Drug Labeling

Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available. Use aseptic technique for single or multiple entry and withdrawal from all containers. When diluting or dissolving drugs, mix thoroughly and use promptly. Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute. Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers. Discard unused portion.

Description

openFDA Drug Labeling

DESCRIPTION Sterile Water for Injection USP is a clear, colorless, odorless liquid. It is sterile, hypotonic, nonpyrogenic, and contains no bacteriostatic or antimicrobial agents. Sterile Water for Injection USP is a diluent or solvent suitable for intravascular injection after first having been made approximately isotonic by the addition of suitable solute. pH: 5.5 (5.0–7.0) Not made with natural rubber latex, PVC or DEHP. The plastic container is made from a multilayered film specifically developed for parenteral drugs. It contains no plasticizers and exhibits virtually no leachables. The solution contact layer is a rubberized copolymer of ethylene and propylene. The container is nontoxic and biologically inert. The container-solution unit is a closed system and is not dependent upon entry of external air during administration. The container is overwrapped to provide protection from the physical environment and to provide an additional moisture barrier when necessary. Addition of medication should be accomplished using complete aseptic technique. The closure system has two ports; the one for the administration set has a tamper evident plastic protector and the other is a medication addition site. Refer to the Directions for Use of the container.

OVERDOSAGE Overdosage (hypotonic expansion) is a function of an increase in fluid intake over fluid output, and occurs when the increase in the volume of body fluids is due to water alone. Overdosage may occur in patients who receive large quantities of electrolyte-free water to replace abnormal excessive fluid losses, in patients whose renal tolerance to water loads is exceeded, or in patients who retain water postoperatively in response to stress. Manifestations of water intoxication are behavioral changes (confusion, apathy, disorientation and attendant hyponatremia), central nervous system disturbances (weakness, muscle twitching, headaches, nausea, vomiting, convulsions) and weight gain. Treatment consists of withholding fluids until excessive water is excreted. In severe hyponatremia it may be necessary to cautiously administer hypertonic saline to increase extracellular osmotic pressure and excretion of excess water by the kidneys.

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Sterile Water for Injection, USP is supplied in the following: Store at 20 to 25C (68 to 77F). [See USP Controlled Room Temperature.] Product repackaged by: Henry Schein, Inc., Bastian, VA 24314 From Original Manufacturer/Distributor's NDC and Unit of Sale To Henry Schein Repackaged Product NDC and Unit of Sale Total Strength/Total Volume (Concentration) per unit NDC 0409-4887-10 Tray of 25 Single-Dose Plastic Fliptop Vials NDC 0404-9959-10 1 10 mL Single-Dose Plastic Fliptop Vial in a bag (Vial bears NDC 0409-4887-17) 10 mL NDC 0409-4887-20 Tray of 25 Single-Dose Plastic Fliptop Vials NDC 0404-9959-20 1 20 mL Single-Dose Plastic Fliptop Vial in a bag (Vial bears NDC 0409-4887-23) 20 mL NDC 0409-4887-50 Tray of 25 Single-Dose Plastic Fliptop Vials NDC 0404-9959-50 1 50 mL Single-Dose Plastic Fliptop Vial in a bag (Vial bears NDC 0409-4887-24) 50 mL Distributed by Hospira, Inc., Lake Forest, IL 60045 USA LAB-1292-2.0 Revised: 05/2021 Image1.jpg

Adverse event reports

Source: openFDA FAERS
19,134
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: WATER. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Recalls

Source: FDA Enforcement
Drug recall enforcement reports associated with this product.
Classification Reported Firm Reason Status
Class II April 29, 2026 B BRAUN MEDICAL INC Lack of Assurance of Sterility; potential for leakage from the diaphragm port once the foil is removed. Ongoing
Class II September 24, 2025 B BRAUN MEDICAL INC Lack of Assurance of Sterility- Potential for fluid leakage from the port due to port misalignment. Ongoing
Class II March 8, 2023 Nephron Sc Inc CGMP Deviations: Potential product carryover. Terminated
Class II February 1, 2023 Nephron Sc Inc CGMP Deviations: potential for trace amounts of product carryover. Terminated
Class II May 26, 2021 Pfizer Inc. Presence of Particulate Matter: particulate matter identified as an insect in one vial. Terminated

Shortages

Source: FDA Drug Shortages
Availability records from the FDA Drug Shortages database.
Status Availability Company Presentation Updated
Current Available Hospira, Inc., a Pfizer Company Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-99) September 22, 2026
Current Available Hospira, Inc., a Pfizer Company Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-50) September 22, 2026
Current Available B. Braun Medical Inc. Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0264-2101-00) September 22, 2026
Current Available Hospira, Inc., a Pfizer Company Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-20) September 22, 2026
Current Available Hospira, Inc., a Pfizer Company Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-10) September 22, 2026
Current Available B. Braun Medical Inc. Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0264-2101-10) September 22, 2026
Current Available Hikma Pharmaceuticals USA, Inc. Sterile Water, Injection, 1 mL/1 mL (NDC 0641-6147-10) September 18, 2026
Current Available Baxter Healthcare Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-02) September 17, 2026
Current Available Baxter Healthcare Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-03) September 17, 2026
Current Limited Availability Baxter Healthcare Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-04) September 17, 2026
Current Available Medefil, Inc. Sterile Water, Injection, 10 mL/10 mL (NDC 64253-020-30) September 15, 2026
Current Available Fresenius Kabi USA, LLC Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-50) September 15, 2026
Current Unavailable Fresenius Kabi USA, LLC Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-10) September 15, 2026
Current Available Fresenius Kabi USA, LLC Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-20) September 15, 2026
Current Available Fresenius Kabi USA, LLC Sterile Water, Injection, 1000 mL/1000 mL (NDC 63323-178-76) September 15, 2026
Current Limited Availability Nephron Pharmaceuticals Corporation Sterile Water, Injection, 1 mL/1 mL (NDC 0487-6105-01) August 4, 2026

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
50090-2874-1 50090-2874 A-S Medication Solutions 25 VIAL, PLASTIC in 1 TRAY (50090-2874-1) / 10 mL in 1 VIAL, PLASTIC February 17, 2017
76420-082-10 76420-082 Asclemed USA, Inc. 10 mL in 1 VIAL, PLASTIC (76420-082-10) April 9, 2020
0264-7385-50 0264-7385 B. Braun Medical Inc. 4 CONTAINER in 1 CASE (0264-7385-50) / 2000 mL in 1 CONTAINER September 4, 2014
0264-7385-60 0264-7385 B. Braun Medical Inc. 4 CONTAINER in 1 CASE (0264-7385-60) / 3000 mL in 1 CONTAINER September 4, 2014
0264-7850-00 0264-7850 B. Braun Medical Inc. 12 CONTAINER in 1 CASE (0264-7850-00) / 1000 mL in 1 CONTAINER February 24, 1988
0264-7850-10 0264-7850 B. Braun Medical Inc. 24 CONTAINER in 1 CASE (0264-7850-10) / 500 mL in 1 CONTAINER February 24, 1988
0264-7850-20 0264-7850 B. Braun Medical Inc. 24 CONTAINER in 1 CASE (0264-7850-20) / 250 mL in 1 CONTAINER February 24, 1988
17271-802-07 17271-802 Becton Dickinson and Company 6 BAG in 1 CASE (17271-802-07) / 1000 mL in 1 BAG January 2, 2026
17271-802-08 17271-802 Becton Dickinson and Company 5 BAG in 1 CASE (17271-802-08) / 2000 mL in 1 BAG January 2, 2026
17271-802-09 17271-802 Becton Dickinson and Company 4 BAG in 1 CASE (17271-802-09) / 3000 mL in 1 BAG November 14, 2025
55154-0127-5 55154-0127 Cardinal Health 107, LLC 5 VIAL, PLASTIC in 1 BAG (55154-0127-5) / 10 mL in 1 VIAL, PLASTIC September 15, 2011
55154-9588-5 55154-9588 Cardinal Health 107, LLC 5 VIAL in 1 BAG (55154-9588-5) / 10 mL in 1 VIAL October 31, 2024
62135-833-84 62135-833 Chartwell RX, LLC 30 VIAL, SINGLE-DOSE in 1 CARTON (62135-833-84) / 5 mL in 1 VIAL, SINGLE-DOSE January 25, 2024
63323-185-05 63323-185 Fresenius Kabi USA, LLC 25 VIAL, SINGLE-DOSE in 1 TRAY (63323-185-05) / 5 mL in 1 VIAL, SINGLE-DOSE (63323-185-04) April 30, 2022
63323-185-10 63323-185 Fresenius Kabi USA, LLC 25 VIAL in 1 TRAY (63323-185-10) / 10 mL in 1 VIAL (63323-185-07) September 5, 2000
63323-185-20 63323-185 Fresenius Kabi USA, LLC 25 VIAL in 1 TRAY (63323-185-20) / 20 mL in 1 VIAL (63323-185-08) September 5, 2000
63323-185-50 63323-185 Fresenius Kabi USA, LLC 25 VIAL in 1 TRAY (63323-185-50) / 50 mL in 1 VIAL (63323-185-09) September 5, 2000
65219-187-10 65219-187 Fresenius Kabi USA, LLC 25 VIAL, SINGLE-DOSE in 1 TRAY (65219-187-10) / 100 mL in 1 VIAL, SINGLE-DOSE (65219-187-01) April 29, 2022
65219-495-10 65219-495 Fresenius Kabi USA, LLC 6 BAG in 1 CASE (65219-495-10) / 1000 mL in 1 BAG (65219-495-01) December 19, 2025
65219-497-20 65219-497 Fresenius Kabi USA, LLC 5 BAG in 1 CASE (65219-497-20) / 2000 mL in 1 BAG (65219-497-02) December 19, 2025
65219-499-30 65219-499 Fresenius Kabi USA, LLC 4 BAG in 1 CASE (65219-499-30) / 3000 mL in 1 BAG (65219-499-03) March 3, 2025
51662-1265-1 51662-1265 HF Acquisition Co LLC, DBA HealthFirst 50 mL in 1 VIAL, PLASTIC (51662-1265-1) September 17, 2018
51662-1329-1 51662-1329 HF Acquisition Co LLC, DBA HealthFirst 10 mL in 1 VIAL, PLASTIC (51662-1329-1) October 8, 2018
51662-1474-1 51662-1474 HF Acquisition Co LLC, DBA HealthFirst 20 mL in 1 VIAL, PLASTIC (51662-1474-1) December 14, 2019
51662-1266-1 51662-1266 HF Acquisition Co. LLC, DBA HealthFirst 100 mL in 1 VIAL, GLASS (51662-1266-1) September 2, 2018
0404-9959-10 0404-9959 Henry Schein, Inc. 1 VIAL, SINGLE-DOSE in 1 BAG (0404-9959-10) / 10 mL in 1 VIAL, SINGLE-DOSE January 12, 2022
0404-9959-20 0404-9959 Henry Schein, Inc. 1 VIAL, SINGLE-DOSE in 1 BAG (0404-9959-20) / 20 mL in 1 VIAL, SINGLE-DOSE January 12, 2022
0404-9959-50 0404-9959 Henry Schein, Inc. 1 VIAL, SINGLE-DOSE in 1 BAG (0404-9959-50) / 50 mL in 1 VIAL, SINGLE-DOSE January 12, 2022
0404-9971-00 0404-9971 Henry Schein, Inc. 1 VIAL, GLASS in 1 BAG (0404-9971-00) / 100 mL in 1 VIAL, GLASS January 10, 2022
0409-0024-10 0409-0024 Hospira, Inc. 25 VIAL, SINGLE-DOSE in 1 TRAY (0409-0024-10) / 10 mL in 1 VIAL, SINGLE-DOSE (0409-0024-01) March 31, 2025
0409-4887-10 0409-4887 Hospira, Inc. 25 VIAL, PLASTIC in 1 TRAY (0409-4887-10) / 10 mL in 1 VIAL, PLASTIC (0409-4887-17) August 1, 2005
0409-4887-20 0409-4887 Hospira, Inc. 25 VIAL, PLASTIC in 1 TRAY (0409-4887-20) / 20 mL in 1 VIAL, PLASTIC (0409-4887-23) June 16, 2005
0409-4887-34 0409-4887 Hospira, Inc. 30 VIAL, PLASTIC in 1 TRAY (0409-4887-34) / 10 mL in 1 VIAL, PLASTIC (0409-4887-32) July 30, 2015
0409-4887-50 0409-4887 Hospira, Inc. 25 VIAL, PLASTIC in 1 TRAY (0409-4887-50) / 50 mL in 1 VIAL, PLASTIC (0409-4887-24) August 4, 2005
0409-4887-99 0409-4887 Hospira, Inc. 25 VIAL, GLASS in 1 CASE (0409-4887-99) / 100 mL in 1 VIAL, GLASS (0409-4887-25) August 3, 2005
71872-7290-1 71872-7290 Medical Purchasing Solutions, LLC 1 VIAL, PLASTIC in 1 BAG (71872-7290-1) / 20 mL in 1 VIAL, PLASTIC June 3, 2022
0487-6105-01 0487-6105 Nephron Pharmaceuticals Corporation 30 VIAL, PLASTIC in 1 CARTON (0487-6105-01) / 5 mL in 1 VIAL, PLASTIC June 16, 2021
84549-850-10 84549-850 ProPharma Distribution 500 mL in 1 CONTAINER (84549-850-10) September 18, 2025
84549-887-50 84549-887 ProPharma Distribution 50 mL in 1 VIAL, PLASTIC (84549-887-50) August 27, 2025
70518-4732-1 70518-4732 REMEDYREPACK INC. 25 VIAL, PLASTIC in 1 TRAY (70518-4732-1) / 10 mL in 1 VIAL, PLASTIC (70518-4732-0) August 23, 2026
50090-2874 50090-2874 A-S Medication Solutions — June 16, 2005
76420-082 76420-082 Asclemed USA, Inc. — June 16, 2005
0264-7385 0264-7385 B. Braun Medical Inc. — September 4, 2014
0264-7850 0264-7850 B. Braun Medical Inc. — February 24, 1988
17271-802 17271-802 Becton Dickinson and Company — November 14, 2025
55154-0127 55154-0127 Cardinal Health 107, LLC — September 15, 2011
55154-9588 55154-9588 Cardinal Health 107, LLC — October 31, 2024
62135-833 62135-833 Chartwell RX, LLC — June 7, 2021
63323-185 63323-185 Fresenius Kabi USA, LLC — September 5, 2000
65219-187 65219-187 Fresenius Kabi USA, LLC — April 29, 2022
65219-495 65219-495 Fresenius Kabi USA, LLC — December 19, 2025
65219-497 65219-497 Fresenius Kabi USA, LLC — December 19, 2025
65219-499 65219-499 Fresenius Kabi USA, LLC — March 3, 2025
51662-1265 51662-1265 HF Acquisition Co LLC, DBA HealthFirst — September 17, 2018
51662-1329 51662-1329 HF Acquisition Co LLC, DBA HealthFirst — October 8, 2018
51662-1474 51662-1474 HF Acquisition Co LLC, DBA HealthFirst — December 14, 2019
51662-1266 51662-1266 HF Acquisition Co. LLC, DBA HealthFirst — September 2, 2018
0404-9959 0404-9959 Henry Schein, Inc. — January 12, 2022
0404-9971 0404-9971 Henry Schein, Inc. — January 10, 2022
0409-0024 0409-0024 Hospira, Inc. — March 31, 2025
0409-4887 0409-4887 Hospira, Inc. — June 16, 2005
71872-7290 71872-7290 Medical Purchasing Solutions, LLC — June 16, 2005
0487-6105 0487-6105 Nephron Pharmaceuticals Corporation — June 7, 2021
84549-850 84549-850 ProPharma Distribution — February 24, 1988
84549-887 84549-887 ProPharma Distribution — June 16, 2005
70518-4732 70518-4732 REMEDYREPACK INC. — August 23, 2026

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts
Enforcement FDA Recall records
Drug Shortages FDA Supply availability

Generated September 25, 2026 · 13 sections on this page.